SCHEMBL4716701

SCHEMBL4716701

CC(C)CCCC(C)CCCC(C)CCCC(C)CCOC(=O)c1ccccc1O

nearest known ligand 0.60

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.60
EGFR P00533 2/20 0.56
LMNA P02545 3/20 0.50
TSHR P16473 6/20 0.46
ALDH1A1 P00352 5/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPK1 P28482 1/20 0.44
ALOX5 P09917 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24691227 1.00 TDP1 (0.60) TDP1EGFRLMNATSHRALDH1A1
SCHEMBL24691964 1.00 TDP1 (0.60) TDP1EGFRLMNATSHRALDH1A1
SCHEMBL3221436 0.91 TSHR (0.56) TDP1EGFRLMNATSHRALDH1A1
SCHEMBL113328 0.88 TDP1 (0.67) TDP1LMNATSHRALDH1A1L3MBTL1
SCHEMBL17978239 0.88 TDP1 (0.67) TDP1LMNATSHRALDH1A1L3MBTL1
SCHEMBL29449291 0.88 TDP1 (0.67) TDP1LMNATSHRALDH1A1L3MBTL1
SCHEMBL63546 0.86 TDP1 (0.69) TDP1LMNATSHRALDH1A1L3MBTL1
SCHEMBL4922318 0.86 TDP1 (0.69) TDP1LMNATSHRALDH1A1L3MBTL1
SCHEMBL597679 0.86 TDP1 (0.69) TDP1LMNATSHRALDH1A1L3MBTL1
SCHEMBL32671557 0.86 TDP1 (0.69) TDP1LMNATSHRALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101404985-A Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB PUBL (SE) 2009-04-08 CN disclosed
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 TDP1 1932/4885EGFR 4761/4885LMNA 4180/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.